Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

22 The results of a planned second interim analysis of OS (at data cut‐off date of November 30, 2015), undertaken after a total of 101 deaths (53% of the total targeted 191 deaths for final OS analysis), continued to suggest a positive trend for survival benefit with everolimus, although statistical significance was not achieved. 28 Overall survival was immature at the interim analyses.

also in 11,005 other papers